5'-DMT-dC(Ac)-Suc-CPG; 1400 Å

5'-DMT-dC(Ac)-Suc-CPG; 1400 Å is a reagent used in the solid-phase synthesis of oligonucleotides for incorporating acetyl-protected deoxycytidine (dC) residues. It features a 5'-DMT (dimethoxytrityl) protective group to protect the 5' end of the deoxycytidine base, an acetyl group (Ac) to protect the cytidine's exocyclic amino group, and a succinyl (Suc) linker attached to controlled pore glass (CPG) with a 1400 Å pore size. This configuration allows for efficient synthesis and high loading capacity, facilitating precise incorporation of deoxycytidine into DNA sequences while maintaining stability and ease of deprotection.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Catalog

BRP-02267

Synonyms

5'-DMT-dC(Ac)-CPG; 1400 Å; 5'-O-DMT-2'-deoxy-C(Ac)-3'-O-Suc-CPG; 1400 Å

Appearance

White powder

Storage

Store at 2-8 °C

Shipping

Room temperature.

Cleavage Conditions

Use concentrated ammonia for 90 min at 25°C or 30 min at 60°C, or 1:1 ammonia:methylamine (AMA) for 25 min at 25°C when using fast deprotecting amidites.

Deprotection Conditions

When using fast deprotection amidites (such as C-Ac; G-DMF), use concentrated ammonia at 60°C for 1h or AMA for 30 min. When using standard amidites (such as C-Bz; G-iBu), please use concentrated ammonia at 60°C for 5h.

Chemical Structure:

Reference Reading

1. [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617

Sarah D Busslinger, Viviane J Tschan, Olivia K Richard, Zeynep Talip, Roger Schibli, Cristina Müller. Cancers (Basel). 2022 Nov 17;14(22):5651. doi: 10.3390/cancers14225651.

In the present study, SibuDAB, an albumin-binding PSMA ligand, was investigated in combination with actinium-225 and the data were compared with those of [225Ac]Ac-PSMA-617. In vitro, [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617 showed similar tumor cell uptake and PSMA-binding affinities as their 177Lu-labeled counterparts. The in vitro binding to serum albumin in mouse and human blood plasma, respectively, was 2.8-fold and 1.4-fold increased for [225Ac]Ac-SibuDAB as compared to [177Lu]Lu-SibuDAB. In vivo, this characteristic was reflected by the longer retention of [225Ac]Ac-SibuDAB in the blood than previously seen for [177Lu]Lu-SibuDAB. Similar to [225Ac]Ac-PSMA-617, [225Ac]Ac-SibuDAB was well tolerated at 30 kBq per mouse. Differences in blood cell counts were observed between treated mice and untreated controls, but no major variations were observed between values obtained for [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617. [225Ac]Ac-SibuDAB was considerably more effective to treat PSMA-positive tumor xenografts than [225Ac]Ac-PSMA-617. Only 5 kBq per mouse were sufficient to eradicate the tumors, whereas tumor regrowth was observed for mice treated with 5 kBq [225Ac]Ac-PSMA-617 and only one out of six mice survived until the end of the study. The enhanced therapeutic efficacy of [225Ac]Ac-SibuDAB as compared to that of [225Ac]Ac-PSMA-617 and reasonable safety data qualify this novel radioligand as a candidate for targeted α-therapy of prostate cancer.

2. Litiasic acute cholecystitis: application of Tokyo Guidelines in severity grading

Alfredo Escartín , Marta González, Pablo Muriel, Elena Cuello, Ana Pinillos, Maite Santamaría, Helena Salvador, Jorge-Juan Olsina. Observational Study. 2021;89(1):12-21. doi: 10.24875/CIRU.19001616.

Acute calculous cholecystitis (AC) is one of the most frequent surgical emergencies in our field. Laparoscopic cholecystectomy is considered the treatment of choice, although not sufficiently widespread. To analyze the application of the Tokyo Guidelines in the management of AC and to determine the influence of the degree of severity on management and prognosis. Prospective, observational study of patients with a primary diagnosis of AC between 2010 and 2015.. Exclusion criteria: AC recurrence; AC as a secondary diagnosis; acalculous cholecystitis; concurrent biliary pathology. Severity was classified according Tokyo 2013 Guidelines. 998 patients were included: 338 (33.9%) mild AC, 567 (56.8%) moderate AC, and 93 (9.3%) severe AC. A total of 582 (58.3%) patients were operated on. Postoperative complications Dindo-Clavien grade ≥ II 12.6%: mild AC 3.6%; moderate AC 12.2%; severe AC 49.0% (p < 0.001). Overall mortality 2%: mild AC 0%; moderate AC 0.5%; severe AC 18.0% (p < 0.001). Urgent laparoscopic cholecystectomy remains the treatment of choice for mild and moderate AC. In patients with severe AC, the risks and benefits of surgery should be assessed, given the high degree of complications and associated mortality.

3. Therapeutic Effects of Anthocyanins for Vision and Eye Health

Yuri Nomi, Keiko Iwasaki-Kurashige, Hitoshi Matsumoto. Review. 2019 Sep 11;24(18):3311. doi: 10.3390/molecules24183311.

Anthocyanin (AC) is widely used as supplement of eye health in Europe and in East Asia. In this review, I describe AC effects to clarify the mechanism is important in order to understand the effects of AC on vision health. The bioavailability of AC is quite low but, reported as intact form and many kinds of metabolite. And AC passes through the blood-aqueous fluid barrier and blood-retinal barrier. In vitro study, AC had a relaxing effect on ciliary muscle which is important to treat both myopia and glaucoma. And AC stimulate the regeneration of rhodopsin in frog rod outer segment. Furthermore, AC could inhibit the axial length and ocular length elongation in a negative lens-induced chick myopia model. In addition, we summarized clinical studies of AC intake improved dark adaptation and transient myopic shift and the improvement on retinal blood circulation in normal tension glaucoma patients.